Clinical trial
Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer
NCT00087035
Study timeline
Study start (unknown)2004-05-01Date precision: month
Registry last updated2020-08-03
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Prostate Cancerunresolved
Interventions
docetaxelDRUG · verified · RxNorm: docetaxel
erlotinib hydrochlorideDRUG · verified · RxNorm: erlotinib hydrochloride
Sponsors & collaborators
Jonsson Comprehensive Cancer Centerlead sponsor
Aventis Pharmaceuticalscollaborator
Genenteccollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00087035 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.